MVI NEWS

Madison Vaccines Announces the Appointment of Michael Richman to its Board of Directors

 

--Extensive Research and Business Experience will Support Development of New Treatment Options for Prostate Cancer--

 

Madison, WI, May 14, 2014 – Madison Vaccines Incorporated (MVI), a clinical stage biopharmaceutical company focused on advancing innovative therapies for prostate cancer, today announced the appointment of Michael Richman to its Board of Directors. Mr. Richman has almost 30 years’ experience working in pharmaceutical research and business development. He helped found Amplimmune, a spinout from Johns Hopkins University, and has since overseen the acquisition of the company by MedImmune, the global biologics research and development arm of AstraZeneca, as a part of their global commitment to immunotherapy and developing novel medicines for patients.

 

“Michael has an extensive record working in the immune therapy space, possesses highly effective business development acumen, and has seasoned biotech management and governance skills,” said Richard Lesniewski, Ph.D., President of MVI. “We are developing DNA vaccines for prostate cancer patients who might otherwise face castration. Michael’s guidance will be invaluable as we work to extend the quality and length of life for men with recurrent disease.”

 

Mr. Richman has held positions in companies including Chiron Corporation (now Novartis), MacroGenics and MedImmune, Inc. (now Astra Zeneca), where he was Senior Vice President Corporate Development. While at MedImmune, Mr. Richman drove over $1.6 billion in transactions. He has now come full circle with Amplimmune now being part of MedImmune. Mr. Richman obtained his B.S. in Genetics/Molecular Biology at the University of California at Davis and his M.S.B.A. in International Business at San Francisco State University.

 

 

 

About MVI

 

The principal mission of Madison, Wisconsin-based MVI is the development of therapeutic plasmid DNA vaccine products for patients with prostate cancer.  MVI is also developing a sensitivity test to identify those patients who will derive clinical benefit from these vaccines.  MVI has licensed patented technologies that were developed in the laboratory of Dr. Douglas McNeel at the University of Wisconsin-Madison.  More information is available at www.madisonvaccines.com.

Latest Articles:

MADISON VACCINES INCORPORATED APPOINTS JEFF BAILEY TO ITS BOARD OF DIRECTORS

 

10-26-2017

Return to News